Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Common Equity (2020 - 2025)

Historic Common Equity for TScan Therapeutics (TCRX) over the last 6 years, with Q3 2025 value amounting to $144.0 million.

  • TScan Therapeutics' Common Equity fell 3713.26% to $144.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $144.0 million, marking a year-over-year decrease of 3713.26%. This contributed to the annual value of $241.0 million for FY2024, which is 5972.35% up from last year.
  • TScan Therapeutics' Common Equity amounted to $144.0 million in Q3 2025, which was down 3713.26% from $176.7 million recorded in Q2 2025.
  • Over the past 5 years, TScan Therapeutics' Common Equity peaked at $255.2 million during Q2 2024, and registered a low of -$60.0 million during Q2 2021.
  • Over the past 5 years, TScan Therapeutics' median Common Equity value was $150.9 million (recorded in 2023), while the average stood at $141.4 million.
  • As far as peak fluctuations go, TScan Therapeutics' Common Equity skyrocketed by 47863.97% in 2021, and later plummeted by 4645.08% in 2023.
  • Quarter analysis of 5 years shows TScan Therapeutics' Common Equity stood at $160.8 million in 2021, then tumbled by 38.15% to $99.4 million in 2022, then surged by 51.73% to $150.9 million in 2023, then soared by 59.72% to $241.0 million in 2024, then crashed by 40.23% to $144.0 million in 2025.
  • Its Common Equity stands at $144.0 million for Q3 2025, versus $176.7 million for Q2 2025 and $210.2 million for Q1 2025.